Issue 2 - Jan 12, 2018
Issue 1 - Jan 5, 2018
  • ASCO forms collaboration with two Big Data firms to grow CancerLinQ

    The ten-year collaboration, announced Dec. 21, gives Tempus and PH.AI access to de-identified data from over a growing database of more than a million records contained in CancerLinQ.

    ASCO and its new commercial partners will continue to expand CancerLinQ and, at the same time, look for better ways to aggregate and mine the data. The data could be used in drug development as well as scientific projects and quality initiatives.

  • Conversation with the Cancer Letter

    Hudis: ASCO needed collaborators to help CancerLinQ deliver faster on its mission

    “This is a licensure and a strategic collaboration. This leverages the expertise of several organizations to allow us to deliver real value to our members and subscribers faster than we would have been able to otherwise.”

  • Conversation with the Cancer Letter

    Lefkofsky: CancerLinQ has value in ushering in an era of precision medicine

    “This gets a bit into Tempus’s business model and at least how we view the world. This data has some commercial applicability today. But the real value in this data is in how do you build much larger, much more comprehensive datasets that actually can be used to usher in an era of precision medicine.”

  • Introducing the clinical section of The Cancer Letter

    Today’s issue of The Cancer Letter contains a new section devoted to clinical news.

    As part of our new format, stories that have immediate clinical significance will appear in every issue, much like a sports or business section in a newspaper.

  • An Appreciation

    Jimmie Holland, founder of psycho-oncology, dies at 89

    Jimmie C. Holland, internationally recognized as the founder of the field of psycho-oncology, died suddenly on Dec. 24, 2017, at the age of 89.

  • An Appreciation

    Gerald Hanks, pioneering radiation oncologist, dies at 83

    Gerald E. Hanks was a giant in the world of radiation oncology and oncology in general. It isn’t often that we can say this and probably understate a person’s significance and influence, but Jerry was one of those people.  He died on Dec. 20, 2017, at the age of 83.

  • In Brief

    • Howard “Skip” Burris elected ASCO president for 2019-2020
    • Hochster named associate director, clinical research, and chief of GI med/onc at Rutgers
    • Whitten named president of Taiho Oncology
    • Purdue Center for Cancer Research receives $10 million from Walther Cancer Foundation
    • METAvivor announces 2017 grant awards for metastatic cancer research
    • JAX starts canine cancer initiative to find predictors, treatments for humans, dog
  • TCCL Logo

  • Trials and Tribulations

    Cabozantinib in first-line treatment of metastatic renal cell carcinoma

    Systemic therapies for metastatic renal cell carcinoma (mRCC) have expanded dramatically over the past 3 years.

  • Clinical Roundup

    • CAP publishes guideline to ensure accurate HPV testing in head and neck cancers
    • CAR-T therapy cancer study published in the New England Journal of Medicine
    • Cancer mortality in the U.S. continues decades-long drop
  • Drugs and Targets

    • FDA approves Perjeta in adjuvant breast cancer
    • FDA approves Cabometyx for previously untreated advanced renal cell carcinoma
    • FDA approves Pfizer’s Bosulif (bosutinib) for newly-diagnosed Ph+ CML
    • FDA approves Xgeva for prevention of skeletal-related events in multiple myeloma
    • Kisqali receives breakthrough designation for HR+/HER2- breast cancer
    • FDA accepts sBLA, grants priority review for Adcetris
    • FDA grants breakthrough designation for Avelumab in combination with Inlyta in RCC
    • FDA grants orphan drug designation to Aptose Biosciences for CG’806 in AML
    • FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated NSCLC
    • FDA grants priority review for Apalutamide in non-metastatic castration-resistant prostate cancer
    • Janssen and Legend Biotech enter deal to develop CAR-T therapy
Issue 46 - Dec 15, 2017
  • “We’re gonna free the data,” Sharpless pledges at NCI Town Hall

    In his first talk to  NCI staff, director Norman “Ned” Sharpless presented himself as an institute insider—highlighting his career-long relationships with NCI and its “legends,” demonstrating his grasp of the institute’s agenda and research portfolio.

  • Five health systems join Strata Oncology network to sequence and match patients to targeted therapy trials

    Five health care systems have joined a precision oncology network that sequences patients’ tumors at no cost and matches patients to clinical trials.

  • As FDA, AHRQ spar over incidence estimates for uterine sarcomas, FDA reiterates recommendation to restrict power morcellation

    About one in 225 to one in 580 women who undergo surgery for fibroids may have hidden uterine cancers, FDA concluded in a recent review of medical studies published over the past four years.

    The updated estimate is generally consistent with one contained in the agency’s 2014 review, FDA officials said in a statement Dec. 14. Three years ago,  the agency estimated that  one in 350 women undergoing such surgery may have a previously undiagnosed sarcoma.

  • Anticipating fundamental change in oncology

    In 2017, The Cancer Letter’s readership grew by over 40 percent and the number of page views has nearly doubled from the 2016 level.

    On an average day in 2017, our website got over 1,700 visits and over 12,500 page views. By way of comparison, in 2016, we gauged 1,200 visits and 6,800 page views. We are losing the right to call ourselves a small publication.

  • In Brief

    • AACR urges House-Senate conference to remove tax bill provisions penalizing future scientists, patients, survivors
    • 2017 AACR-Bayer Innovation and Discovery Grants recipients announced
    • USPSTF recommends against hormone therapy for preventing chronic conditions 
    • Jason Incorvati joins hem/onc department at New Fox Chase East Norriton Campus
  • Drugs and Targets

    • Fate Therapeutics completes technology transfer and starts IND-enabling manufacture of FT500